N/A N=20 A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices
Total Hip Arthroplasty
Primary: Peak Venous Velocity — 127.9; 155.7; 87.1; 86.8 cm/s
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
Neoplasms, Head and Neck
Primary: Number of Participants Achieving Best Overall Response — 7; 3; 1 Participants
N/A N=88 Electrical Stimulation for the Treatment of Chronic Post-Stroke Shoulder Pain Using the Smartpatch System
Post-stroke Shoulder Pain · Hemiplegic Shoulder Pain
Primary: Change From Baseline Shoulder Pain Intensity at End of Treatment (EOT) — 7.1; 6.6; 4.1; 4.1 scores on a scale
Phase 4 N=205 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)
Ulcerative Colitis
Primary: Percentage of Participants Meeting Partial Mayo Score Response Criteria Through Week 54 — 24.9 Percentage of Participants
Phase 2 N=10 Botulinum Toxin A Single Blind Split-Face Randomized Pilot Study
Facial Rhytids
Primary: Blinded Assessment: Overall Change in Facial Wrinkles From Baseline to Week 2 as Assessed by a Numeric Rating Scale Based on Pre- and Post-treatment Photographs — -0.21…
N/A N=61 Offering Free Fruits and Vegetables to Men at Risk of Poverty
Dietary Habits
Primary: Variety of Fruits and Vegetables — 2.6; -1.2 types/day — p=<0.001
Phase 2 N=79 Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Gastroparesis
Primary: Gastric Half Emptying Time (GEt1/2) — 131.2; 106.5; 118.2; 131.1 Minutes
N/A N=20 Developing a COMputerised Bone Age Tool
Bone Diseases, Developmental
Primary: Number of Participants With Observer Agreement Between Bone Age as Assessed From Left Hand and Wrist DXA Compared to Radiographs — 20 Participants
Phase 1 N=20 Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Anti-Psychotic · Management of Manifestations of Psychotic Disorders · Treatment of Schizophrenia
Primary: Maximum Observed Plasma Concentration (Cmax) - Chlorpromazine — 2671; 2720 pg/mL
Phase 4 N=74 Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)
Asthma
Primary: Maximal Percent Decrease in Forced Expiratory Volume in One Second (FEV1) Following Exercise Challenge at 12 Hours (Hrs) Post Evening Dose From Pre-exercise FEV1…
Phase 1 N=15 RDEA3170 Bioavailability Study
Gout
Primary: Maximum Observed Plasma Concentration (Cmax) — 14.1; 14.9 ng/mL
N/A N=71 Long-term Caloric Restriction and Cellular Aging Markers
Aging
Primary: Telomere Length — 0.96; 1.06; 1.06; 1.22 ratio
N/A N=38 The Neurobiology of Expectancy and Pain Perception
Pain
Primary: Subjective Response to Pain (0-20 Visual Analogue Scale) — 10.7; 11; 11.2; 8.1 units on a scale
Phase 2 N=40 Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Psoriasis
Primary: Assessment of Clinical Activity by Improvement Score (Using Krueger Criteria): Number of Participants With Good or Excellent Improvement Score Based on Histological…
Phase 2 N=163 A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
Follicular Lymphoma
Primary: Percentage of Participants With Complete Metabolic Response (CMR) According to Independent Review Committee (IRC) as Per Lugano Classification, Using Positron Emission…